It is currently trading at $23.65 which is impressively higher than the 50 day moving average which is $21.40 and much higher than the 200 day moving average of $21.06. The 50 day moving average was up $2.25 whereas the 200 day average was up by +12.30%. 1,049K shares changed hands by the end of trading on Tuesday. Shares saw a steep increase in trading volume of 89.23% over the normal average daily volume.
Short traders are more bullish on shares of Grifols, S.A. – American Deposi recently if you take note of the change in short interest. The firm experienced a fall in short interest of -9.99% as of October 13, 2017 from the last reporting period. Short interest decreased from 1,141,821 to 1,027,794 over that period. Days to cover increased from 1.0 to 2.0 and the short interest percentage is 0.00% as of October 13.
Here are a few substantial investment firms who have updated their positions. Pictet Asset Management Ltd downsized its position by selling 1,030,283 shares a decrease of 46.0% in the quarter. Pictet Asset Management Ltd owns 1,210,557 shares with a value of $26,499,000. The value of the position overall is down by 44.9%. As of the end of the quarter Beck Mack & Oliver LLC had sold a total of 23,366 shares trimming its stake by 1.5%. The value of the investment in Grifols, S.A. – American Deposi went from $33,972,000 to $34,682,000 a change of 2.1% quarter over quarter.
As of quarter end Gladstone Capital Management LLP had disposed of 302,500 shares trimming its position 30.9%. The value of the investment in (GRFS) decreased from $20,671,616,000 to $14,468,083,000 a change of $6,203,533,000 quarter to quarter. As of quarter end Aperio Group, LLC had bought 5,948 shares growing its holdings by 2.0%. The value of the investment in GRFS went from $6,156,000 to $6,507,000 increasing 5.7% for the reporting period.
Grifols, S.A. – American Deposi currently has a P/E ratio of 49.68 and market cap is 32.32B. As of the latest earnings report the EPS was $0.48 and is expected to be $1.21 for the current year with 1,366,514,000 shares currently outstanding. Analysts expect next quarter’s EPS will be $0.31 and the next full year EPS is anticipated to be $1.34.
Grifols, S.A., a biopharmaceutical company, develops, manufactures, and distributes plasma derivative products in the United States, Canada, Spain, rest of the European Union, and internationally. It specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation, and reagents for use in hospitals and clinics. The company operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. It offers plasma products, which include IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by and in hospitals, such as parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain..